Literature DB >> 21982108

Risk factors for orbital exenteration in periocular Basal cell carcinoma.

Adriana Iuliano1, Diego Strianese, Giovanni Uccello, Agostino Diplomatico, Sabrina Tebaldi, Giulio Bonavolontà.   

Abstract

PURPOSE: To present the proportion of patients with periocular basal cell carcinoma (BCC) who underwent orbital exenteration and to evaluate the significance of the following risk factors: initial tumor site, pathologic features, and initial treatment.
DESIGN: Retrospective, comparative, interventional case series.
METHODS: Charts of all patients with BCC referred to Orbital Unit of the University of Naples "Federico II" between 1984 and 2003 were reviewed. Charts were reviewed for patient demographics, previous treatments, tumor site, clinical presentation, duration of symptoms, and histologic subtype. The main outcomes were recurrence rate, tumor-related deaths, orbital infiltration, and rate of exenteration.
RESULTS: Data (including follow-up) were available for 506 patients. Twenty-eight patients (5.5%) underwent orbital exenteration. For 8 patients (28.5%), orbital exenteration was the first procedure performed. In the exenterated group, the most common tumor site was the medial cantus, whereas in the overall group, it was the lower eyelid (P = .001). The proportion of patients initially treated without margin control was significantly higher in patients undergoing exenteration (P = .0001). Pathologic examination revealed a higher incidence of infiltrative subtype in the exenterated group (P = .00019).
CONCLUSIONS: The need for exenteration for BCC may be significantly higher when the lesion involves a medial canthal location, initial management does not include margin-controlled excision, or pathologic analysis reveals an infiltrative subtype. Margin-controlled excision for periocular BCC and close follow-up after excision for medial canthal BCC may be indicated.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21982108     DOI: 10.1016/j.ajo.2011.08.004

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  12 in total

1.  Vismodegib as eye-sparing adjuvant treatment for orbital basal cell carcinoma.

Authors:  Alon Kahana; Francis P Worden; Victor M Elner
Journal:  JAMA Ophthalmol       Date:  2013-10       Impact factor: 7.389

2.  Total lower lid reconstruction: clinical outcomes of utilizing three-layer flap and graft in one session.

Authors:  Mohammad Taher Rajabi; Fatemeh Bazvand; Seyedeh Simindokht Hosseini; Ali Makateb; Mohammad Bagher Rajabi; Syed Ziaeddin Tabatabaie; Yalda Abrishami
Journal:  Int J Ophthalmol       Date:  2014-06-18       Impact factor: 1.779

3.  Orbital metastases in Italy.

Authors:  Patrizio Magliozzi; Diego Strianese; Paola Bonavolontà; Mariantonia Ferrara; Pasquale Ruggiero; Raffaella Carandente; Giulio Bonavolontà; Fausto Tranfa
Journal:  Int J Ophthalmol       Date:  2015-10-18       Impact factor: 1.779

Review 4.  Oculoplastic aspects of ocular oncology.

Authors:  C Rene
Journal:  Eye (Lond)       Date:  2012-11-30       Impact factor: 3.775

5.  Infiltrating basal cell carcinoma: a stellate peri-tumor dermatoscopy pattern as a clue to diagnosis.

Authors:  John H Pyne; Paul Fishburn; Anthony Dicker; Michael David
Journal:  Dermatol Pract Concept       Date:  2015-04-30

6.  Superpulsed CO 2 Laser with Intraoperative Pathologic Assessment for Treatment of Periorbital Basal Cell Carcinoma Involving Eyelash Line.

Authors:  Ali Ebrahimi; Mansour Rezaei; Reza Kavoussi; Mojtaba Eidizadeh; Seyed Hamid Madani; Hossein Kavoussi
Journal:  Dermatol Res Pract       Date:  2014-10-13

7.  Periocular Basal Cell Carcinoma Predictors for Recurrence and Infiltration of the Orbit.

Authors:  Alena Furdova; Pavol Lukacko
Journal:  J Craniofac Surg       Date:  2017-01       Impact factor: 1.046

Review 8.  Ocular basal cell carcinoma: a brief literature review of clinical diagnosis and treatment.

Authors:  Yingyun Shi; Renbing Jia; Xianqun Fan
Journal:  Onco Targets Ther       Date:  2017-05-08       Impact factor: 4.147

9.  Orbital lymphoma mimicking lacrimal gland pleomorphic adenoma.

Authors:  Diego Strianese; Andrea Elefante; Francesco Matarazzo; Angela Panico; Mariantonia Ferrara; Fausto Tranfa
Journal:  Case Rep Ophthalmol       Date:  2013-09-17

10.  UV imaging reveals facial areas that are prone to skin cancer are disproportionately missed during sunscreen application.

Authors:  Harry Pratt; Kareem Hassanin; Lee D Troughton; Gabriela Czanner; Yalin Zheng; Austin G McCormick; Kevin J Hamill
Journal:  PLoS One       Date:  2017-10-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.